Vivione Biosciences Inc. announced the successful completion of its early stage pilot study at the Cleveland Clinic focused on applying its RAPID-B bacterial detection platform to the primary screening of suspected urinary tract infections (UTIs). The Vivione's RAPID-B platform, which is currently commercialized in both the Food Safety and the Oil and Gas sectors, is a highly sensitive and rapid platform for detecting bacteria in complex matrices (like beef or frac water). Vivione is currently applying the system not only to urinary tract infection screening but blood infections and meningitis screening as well.

Vivione has also recently filed IP focused around rapid antibiotic susceptibility determination using the RAPID-B platform.